Azura Ophthalmics Ltd.

Azura Ophthalmics Ltd.

Azura Ophthalmics operates as a development-stage pharmaceutical company, not a family office or asset manager. Founded to address a large gap in ocular surface disease, the firm centers its pipeline on Meibomian Gland Dysfunction (MGD), the primary cause of evaporative dry eye. A 2023 article in Ocular Surgery News highlighted AZR-MD-001 as the first therapeutic candidate to directly target keratinization of the meibomian glands. The firm has raised multiple financing rounds, with investors including Novartis Venture Fund and other life sciences VCs, per the firm's past press releases. Its clinical program spans Phase 2 trials, with data readouts reported in peer-reviewed journals. The geographic footprint is largely Israel and the United States, with clinical sites in both countries. Team size and exact staffing remain undisclosed. The single office is in Herzliya, a biotech hub outside Tel Aviv. Azura has not disclosed any recent operational event within the last 24 months, nor does it operate adjacent vehicles such as foundations or co-investment structures. Azura's structural differentiator is its focused pipeline — single-indication, single-asset — a stark contrast to broader ophthalmic platforms. Its therapeutic claim rests on a novel mechanism (lubricin-like activity) that targets the physical obstruction of glands, rather than suppressing inflammation, a distinction referenced in the American Academy of Ophthalmology's annual meeting abstracts.